Formulation and in vitro evaluation of modified release Gliclazide tablet

Journal of Chemical and Pharmaceutical Research

Volumn 3, Issue 3, 2011, Pages 348-352

  Labana, Mahendra ^a   Srivatava, Birendra ^a  

^a JAIPUR NATIONAL UNIVERSITY   (India)

Author keywords

Dibasic calcium phosphate and Maltodextrin; HPMC; MR Gliclazide

Indexed keywords

CALCIUM PHOSPHATE DIBASIC; GLICLAZIDE; HYDROXYPROPYLMETHYLCELLULOSE; MALTODEXTRIN;

ARTICLE; DRUG DOSAGE FORM COMPARISON; DRUG INTERACTION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; PH; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS;

EID: 79957897157     PISSN: None     EISSN: 09757384     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. nd ed. London: ELBS/ Churchill Livingstone; 2002. p. 4.
2. th ed. Vol. 1. New York: Lippincott Williams and Wilkins; 2000. p. 903.
3. st Ed. New Delhi: CBS Publications; 2004. p. 1-2.
4. th ed. vol 1. U.S. A: Lippincott Williams and Wilkins; 2000. p. 660-63.
5. Sansom Lloyd N. Oral extended-release products. In: Therapeutic Guidelines Ltd, 1999; 22: 88-90.
6. rd ed. p. 576-8.
7. nd ed. New York: Marcel Dekker; 1987. p. 7.
8. Lachman Leon, Lieberman Herbert A. Pharmaceutical Dosage Forms: Tablets. In: The Theory and Practice of Industrial Pharmacy. 2nd ed. Vol 1. U.S. A: Lea and Fibiger; 2002. p. 247-84.
9. Robinson JR, Eriksen, J. Pharm. Sci. 1966; 55: 1254.
10. th ed. Vol. II, 1995. p. 1662.
11. st ed. Delhi; Vallabh Prakashan: 2002.
12. Prithiviraj A, Bhaskar K, Ramachandran S, Saravanan M, Vinod R. Eudragit, Chem. Parma Bull. 2002; 50(11):1495-8.
13. Ballagi-Pordány G, Köszeghy A, Koltai MZ, Aranyi Z, Pogátsa G (January 1990). Diabetes Res. Clinical. Pract. 8 (2): 109-14.
14. Shimoyama T, Yamaguchi S, Takahashi K, et al (2006). Metabolism-Clinical and Experimental 55 (6): 722-30.
15. Rieutord A, Stupans I, Sheffield GM, Gross AS. Xenobiotica 1995; 25: 1345-54.
16. Identification of the human cytochromes P450 catalyzing the rate-limiting pathways of gliclazide elimination. Elliot DJ, Suharjono, Lewis BC, Gilliam EM, Birkett DJ, Gross AS, Miners JO. Br J Clinical Pharmacology. 2007
17. Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clinical Pharmacology There 2003; 74: 334-40.